al. 2002. Accelerating the development and introduction of dengue vaccine fool' poor children, 5-8 December 2001, Ho Chi Minh City, VietNam.
Vaccine, 20: p. 3043-3046.
Amin P., Bhandare S., and Srivastava A 2001. Dengue, Dengue Haemorrhagic
Fever,
Dengue
Shock
Syndrome.
http://www.bl1i.orQ.!journal/200I 4303 iulvOlircvicw 380.11t111
27-04-2004.
Anderson R, Wang S., Osiowy C. and Issekutz AC. 1997. Activation of Endothelial Cells via Antibody-enhanced Dengue Virus infection of Peripheral Blood Monocytes. 1. Virol., 71 (6): p. 4226-4232.
Anna
Durbin,
Phase
I
http://c linicaltrials. gOY!ct{Q.ui!infilipharu~ssjonid=269
3] 9642BSC64CBEB
7BFAB09B4BB133, 9 ok'1ober2004).
Bancroft W.R., Top, Jr F.R., Eckels K.H, Anderson, Jr. lH, McCown lM., and Russell P.K. 1981. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. l1?fect Immlln., 31 (2): p. 698-703.
Bhamarapravati N. and Y oksan S. 1997. Live attenuated tetravalent dengue vaccine. In DJ. Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University press. p. 367-377.
. 2000. Live attenuated tetravalent dengue vaccine. Vaccine, 18 (2): p. 44-47.
Blaney lE. Jr, Manipon G.G., Firestone c.Y, Johnson D.H, Hanson c.T., Murphy RR, et al. 2003. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells. Vaccine, 21 (27-30): p. 4317-27.
Blaney Jr lE., Johnson D.H, Firestone c.Y, Hanson C.T., Murphy B.R, and
Whitehead
S.S.
2001.Chemical Mutagenesis of Dengue Virus Type
4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or
Human Liver Cells and Attenuated in Mice.
Journal of Virology,
75 (20): p.
9731-40.
Bosch I., Xhaja K., Estevez L., Raines G., Melichar H, Warke RY., et al. 2002. Increased Production of Interleukin-8 in Primary Human Monocytes and in
Human Epithelial and Endothelial Cell Lines after Dengue Virus Challenge.
Journal of Virology,
76 (11): p. 5588-5597.
Bosch 1. 2003. Gene Expression of Host Cells Infected with Dengue Virus.
http://\yww.ipk .sId. cui curSO-Q~l}gUC-memoria s/confcrcncias- roam stralc s/23. pdf ,28-01-2005.Bray M., Men R., and Lai C.I. 1996. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J Virol., 70 (6): p. 4162-4166.
Bumi c., Rantam F.A, Soegijanto S., dan Hamid 1.S. 2004. Determinan virulensi virus dengue. In Soegeng Soegijanto: Demam berdarah dengue: tiryauan OOn temuan bam di era 2003. Surabaya: Airlangga University Press. p. 91-97.
Catteau A, Roue G., Yuste V.I., Susin S.A, and Despres P. 2003. Expression of
dengue ApoptoM sequence results in disruption of mitochondrial potential
and caspase activation.
Biochimie,
85 (8): pp. 789-793.
CDS.1999.
Regional
guidenesson
Dengue/DHF
prevention
and
control.
http://ww\v.org/whosea/cds!index.htl11 , 13-] 0-2004.
Cella M., Salio M., Sakakibara Y, Langen R., Julkllnen 1., and Lanzavecchia A 1999. Maturation, activation, and protection of dendritic cells induced by double stranded RNA J Exp. Med, 189 (5): p. 821-829.
Chambers T.I., Liang Y, Droll D.A, Schlesinger J.J, Davidson AD., Wright PJ., et al. 2003. Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model. Journal of Virology, 77 (6): p. 3655-3668.
Chang D.M.
and Shaio M.F.1994. Production of interleukin-l (lL-l) and lL-l
inhibitor by human monocytes exposed to dengue virus.
Journal of
Infectious Diseases,
170 (4): pp. 811-817.
Chang G.J. 1997. Molecular biology of dengue viruses. In DJ. Gubler and G.
Kune:
Dengue and Dengue Hemorrhagic Fever.
Cambridge: University
press. p. 175-198.
Chang G.I., Kuno G., Purdy D.E., and Davis B.S. 2004. Recent advancement in flavivirus vaccine development. Expert Rev 'Vaccines., 3 (2): p. 199-220. Chang HH., Shyu H.F., Wang YM., Sun D.S., Shyu RH, Tang S.S., et al. 2002.
protein 1 (NS1): Arginine-glycine-aspartic acid structural mimicry within
the dengue viral NS 1 antigen.
Journal of ltifectious Diseases,
] 86 (6): pp.
743-751.
Chao D.Y, Lin T.H., Hwang KP., Huang J.H., Liu c.c.,
and King C.C.1998.
dengue
hemoIThagic
fever
epidemic
in
Taiwan.
L/'iDV\\'..~d_~£QyincidO(EEfJ)Iy_ol1 Ono3/0_~::(L'J_~htm, 27-04-2004.
Chaturvedi u.c., Elbishbishi E.A, Agarwal R, and Mustafa AS. 2001. Cytotoxic
factor-autoantibodies:
possible
role
in the
pathogenesis
of
dengue
haemorrhagic fever FEMS.
Immunology
&
Medical Microbiology,
30 (3):
pp. 181-186.
Chen yc.
and Wang S.Y 2002. Activation of Terminally Differentiated Human
Monocytes/Macrophages
by
Dengue
Virus:
Productive
Infection,
Hierarchical Production of Innate Cytokines and Chemokines, and the
Synergistic Effect of Lipopolysaccharide.
Journal of Virology,
76 (19): p.
9877-9887.
Chen YP., Maguire T., Hileman RE., Fromm J.R, Esko J.D., Linhardt RJ. et a1. 1997. Dengue virus infectivity depends on envelope protein binding to target cel1 heparan sulfate. Nature Medicine, 3 (8): p. 866-871.
Chung N.P.Y, Chen Y, Chan V.S.F., TAM P.KH., and Lin c.L.S. 2004. Dendritic cells: sentinels against pathogens. Histology and Histopathology,
]9 (1): p. 317-314.
Chungue E., Poli L., Roche c., Gestas P., Glaziou P., and Markoff LJ. 1994. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J l1ifect Dis., 170 (5): p. ] 304-7. Craig S., Myat Thu H., Lowry K, Wang x.F., Holmes E.C., and Aaskov J. 2003.
Diverse dengue type 2 virus population contain recombinant and both parental viruses in a single mosqiuto host. Journal of T'irology, 77 (7): p. 4463-4467.
Diamond M.S., Edgil D., Roberts T.G., Lu B., and Harris E. 2000. Infection of Human Cel1s by Dengue Virus Is Modulated by Different Cel1 Types and Viral Strains. Journal ofTTirology, 74 (17): p. 7814-7823.
Durbin AP., Karron RA,
Sun W., Vaughn D.W., Reynolds M.l, Perreault lR,
et aI. 200]. Attenuation and Immunogenecity in Humans of Live Dengue
Virus type-4 Vaccine Candidate with 30 Nucleotide Deletion in its
3'-Untranslated Region.
Am. J Trop. Med. Hyg.,
65 (5): p. 405-413.
Eckels
KH.
and Putnak R
2003. Formalin-inactivated
whole virus and
recombinant subunit flavivirus vaccines.
Adv Vims Res,
61: p. 395-418.
Eckels KH., Scott RM., Bancroft W.H., Brown l, Dubois D.R, Summers P.L.,
et al. ]984. Selection of attenuated dengue 4 viruses by serial passage in
primary kidney cells. V. Human response to immunization with a candidate
vaccine prepared in fetal rhesus lung cells.
Am J Trop Med Hyg.,
33 (4): p.
684-9.
Edelman R, Wasserman S.S., Bodison S.A, Putnak R.l, Eckels KH., Tang D., et al. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J TropMed Hyg., ;69(6 Suppl):48-60.
Espina L.M., Valero N.J., Hernandez lM., and Mosquera lA 2003. Increased apoptosis and expresion of tumor necrosis factor a caused by infection of cultured of human monocytes with dengue virus. Am. J Trop. Med. Hyg., 68 (1): p. 48-53.
Gagnon S.J., Ennis F.A, and Rothman AL. ]999. Bystander Target Cell Lysis and Cytokine Production by Dengue Virus-Specific Human CDr Cytotoxic T-Lymphocyte Clones. Journal of Virology, 73 (5): p. 3623-3629.
Gagnon S.J., Mori M., Kurane I., Green S., Vaughn D.W., Kalayanarooj S., et al. 2002. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol, 67 (1): p. 4]-6.
Green S., Vaughn D.W., Kalayanarooj S., Nimmannitya S., Suntayakorn S., Nisalak A, et al. ] 999. Early Immune Activation in Acute Dengue Illness Is Related to Development of Plasma Leakage and Disease Severity. The Journal £?!Infectious Diseas'es, ] 79: p. 755-762.
Green S., Kurane I., Edelman R, Tacket CO, Eckels KH., Vaughn D.W., Hoke Jr CH., and Ennis F.A 1993. Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type ] vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J Virol., 67 (10): p. 5962-67.
Guirakhoo F., Arroyo 1., Pugachev KY., Miller c., Zhang Z.X, Weltzin R, et al. 2001. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine. Journal of Virology, 75 (16): p. 7290-7304.
Guirakhoo F., Pugachev K, Arroyo 1., Miller c., Zhang Z.X, Weltzin R, et al.
2002. Viremia and immunogenicity in nonhuman primates of a tetravalent
yellow
fever-denbrue chimeric
vaccine:
genetic
reconstructions,
dose
adjustment, and antibody responses against wild-type dengue virus isolates.
Virology,
298 (1): p. 146-59.
Guirakhoo F., Pugachev K, Zhang Z., Myers G., Levenbook 1., Draper K,et aI.
2004.
Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus
Tetravalent Vaccine Formulations in Nonhuman Primates. Journal qf Virology, 78 (9): p. 4761-4775
Guirakhoo F., Weltzin R, Chambers TJ., Zhang Z.X, Soike K, Ratterree M.,.
Arroyo 1., et aI.
2000.Recombinant Chimeric Yellow Fever-Dengue Type
2 Virus Is Immunogenic and Protective in Nonhuman Primates.
Journal of
Virology,
74 (12): p. 5477-5485.
Guirakhoo F., Zhang Z., Myers G., Johnson B.W., Pugachev K, Nichols R, et aI. 2004. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys. J Virol., 78 (18): p. 9998-10008.
Guzman M.G. 1998. Advances in the development of a vaccine against dengue. Acta Cient Venez., 49 Suppl 1: p. 38-45
Guzman M.G., Rodriguez R, Rodriguez R, Hennida L., Alvarez M., Lazo L., et aI. 2003. Induction of neutralizing antibodies and partial protection fron viral challengge inMacaca Fascicularis immunized with recombinant Dengue 4 virus envelope gycoprotein expressed inPischia pastoris .Am. 1. Trap. Med Hyg., 69 (2): p. 129-134.
Gwinn W., Sun W., Innis B.L., Caudill 1., and King AD. 2003. Serotype-specific TH1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. American Journal of Tropical Medicine & Hygiene, 69 (6): p. 39-47 (SuppI. S).
Halstead S.B. 1988. Pathogenesis of dengue: challenges to molecular biology.
Science,
239 (4839): p. 476-81.
Halstead S.B. 1997. Epidemiology of dengue and dengue hemorrhagic fever. In
D.1. Gubler and G. Kune:
Dengue and Dengue Hemorrhagic Fever.
Cambridge: University press. p. 23-44.
Halstead S.B. and Marchette N.1. 2003. Biologic properties of dengue viruses
following serial passage in primary dog kidney cells: Studies at the
University of Hawaii.
American Journal of Tropical Medicine
&
Hygiene,
69 (6): pp. 5-11 (Supp!. S).
Hanley KA., Manlucu L.R, Manipon G.G., Hanson C.T., Whitehead S.S., Murphy B.R, et a!. 2004. Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine, 22 (25-26): p. 3440-8.
Hanley KA., Lee J.1., Blaney, Jr lE., Murphy B.R., and Whitehead S.S. 2002. Paired Charge-to-Alanine Mutagenesis of Dengue Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host Range, and Mouse Attenuation Phenotypes. Journal (if Virology, 76 (2): p. 525-531.
Harrison V.R, Eckels KH., Sagartz lW., and Russell P.K 1977. Virulence and
immunogenicity
of a temperature-sensitive
dengue-2
virus
in lower
primates.
Infect Immull.,18
(1): p. 151-6.
Henke A. 2002. DNA immunization--a new chance in vaccine research?
Med
A1icrobiollmmunol
(Berl)., 191 (3-4): p. 187-90.
Ho L.1., Wang J.1., Shaio M.F., Kao c.L., Chang D.M., Han S.W., et a!. 2001.
Infection of human dendritic cells by Dengue virus causes cell maturation
and cytokine production.
Journal of Immunology,
166 (3): pp. 1499-1506.
Huang C.Y.H, Butrapet S., Tsuchiya KR, Bhamarapravati N., Gubler D.1., and Kinney RM. 2003. Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development. Journal of Virology, 77 (21): p.
11436-11447.
Inni s B.L. 1997. Antibody responses to dengue virus infection. In D.J. Gubler and
G. Kune:
Dengue and Dengue Hemorrhagic Fever.
Cambridge: University
press. p. 221-243.
Jaiswal S., Khanna N., and Swaminathan S. 2003. Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Denf,>ueVirus Type 2.Journal <?fVirology, 77 (23): p. 12907-12913.
Jan .LT., Chen RH., Ma S.H., Liu c.I., Tsai H.P., Wu H.C., et a1. 2000. Potential Dengue Virus-Triggered Apoptotic Pathway in Human Neuroblastoma Cells: Arachidonic Acid, Superoxide Anion, and NF-KB Are Sequentially Involved. Journal <?fVirology, 74 (18): p. 8680-8691.
Jimenez RO. and da Fonseca B.AL. 2000.Recombinant plasmid expressing a
truncated dengue-2 virus E protein without co-expression of prM protein
induces partial protection in mice.
Vaccine,
19 (6): p.648-654.
Jirakanjanakit
N., Khin M.M., Yoksan S., and Bhamarapravati
N. 1999.
Dynamics of Susceptibility and Transmissibility of the Life Attenuated
Candidate Vaccines l PDK13, 3 PGMK30F3, and
Dengue-4 PDK Dengue-48 After Oral Infection In
Aedes Aegypti. Am. .J Trop. !lIed. Hyg, 61
(4): p. 672-676.
Johnson B.W., Chambers T.V., Crabtree M.B., Guirakhoo F., Monath T.P., and B.R. Miller. 2004.
Analysis of The Replication Kinetics of ChimeraVaxun
DEN 1,2,3,4 Tetravalent Virus Mixture In Aedes aegypti by Real-Time Reverse Transcriptase-Polymerase Chain Reaction. Am. .J. Trop. Med Hyg., 70 (1): p. 89-97.Kanesa-Thasan N., Edelman R, Tacket e.0.
Wasserman S.S., Vaughn D.W.,
Coster T.S., et al. 2003. Phase 1 Studies of Walter reed Army Institute of
Research Candidate Attenuated Dengue Vaccines: Selection of Save and
Immunogenic Monovalent vaccines.
Am. .J Trop. !lIed. Hyg.,
69(6 suppl): p.
17-23.
Kankirawatana P., Chokephaibulkit K., Puthavathana P., Yoksan S., Apintanapong S., and Pongthapisit V. 2000. Dengue infection presenting with central nervous system manifestation. J Child Nellrol., ] 5 (8): p. 544-7 Kamen Gama Baratawidjaja. 2000. Imu17ologi Dasar. Jakarta: FKUI. p. 8.
King C.A, Anderson R., and Marshall lS. 2002. Dengue Virus Selectively Induces Human Mast Cell Chemokine Production. Journal of Virology, 76 (16): p. 8408-19.
King C.A, Marshall lS.,
Alshurafa H., and
Anderson R. 2000. Release of
Vasoactive Cytokines by Antibody-Enhanced Dengue Virus Infection of a
Human Mast Cell/Basophil Line.
Journal of Virology,
74 (15): p.
7146-7150.
Kliks S., Nisalak A, Brandt W.E., and Burke D.S. 1988. Evidence that Maternal
dengue antibodies are important in the development of dengue hemorrhagic
fever in infants.
American Journal C?fTropical Aledicine and Hygiene, 40:
444-451.
Konishi E., Terazawa A, and Imoto 1. 2003. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice. Vaccine, 21 (17-18): p. 1826-1832.
Kunkel T.A 1985. Rapid and efficient site-spesific mutagenesis without phenotypic selection. Proc. Natl. Acad Sci. USA. 82: p. 488-492.
Kuno G. 1997. Factors influencing the transmission of dengue viruses. In DJ. Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University press. p. 61-80.
Kurane I, Innis B.L., Hoke c.H. Jr, Eckels KH., Meager A, Janus l, et al. 1995. T cell activation in vivo by dengue virus infection. J Clin Lab Immunol., 46 (1): p. 35-40.
Kurane I. and Ennis F.A 1997. Immunopathogenesis of dengue virus infections. In D.l Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University press. p. 273-290.
Kurane I., Innis RL., Nimmannitya S., Nisalak A, Rothman AL., Livingston P.G., et al. 1990. Human immune responses to dengue viruses. Southeast AsianJ TropMed Public Health, 21 (4): p. 658-62.
Lai CJ. and Monath T.P. 2003. Chimeric tlaviviruses: novel vaccines against
dengue fever, tick-borne encephalitis, and Japanese encephalitis.
Adv Virus
Res.,
61 :469-509.
Leonard
E
Munstermann.
1995.
)1t.112~/.kl~b~1&~cift:,~tQ~t;!lC _~Q_~!~a.~.gX12li:11_~'g}lltLb1Jll1,05 -0 5-1 004.Libraty D.H., Pichyangkul S., Ajariyakhajorn c., Endy T.P., and Ennis F.A. 2001.
Human Dendritic
Cells
Are Activated
by Dengue
Virus Infection:
Enhancement
by
Gamma
Interferon
and
Implications
for
Disease
Pathogenesis. Journal of Virology, 75 (8): p. 3501-3508.
Libraty D.H., Endy T.P., Houng H.S.H, Green S., Kalayanarooj S., Suntayakorn S., et al. 2002. Differing Influences of Virus Burden and Immune Activation on Disease Severity in Secondary Dengue-3 Virus Infections. The Journal of Infectious Diseases, 185: p. 1213-1221.
Lin YW., Wang K.1., Lei H.Y, Lin YS., Yeh T.M., Liu H.S.,et al. 2002. Virus Replication and Cytokine Production in Dengue Virus-Infected Human B Lymphocytes. Journal of Vim logy, 76 (23): p. 12242-12249.
Lindenbach B.D. and Rice C.M. 1999. Genetic interaction of Flavivirus nonstructural protein NS 1 and NS4 A as a determinant of replicase function. Journal of Virology, 73 (6): p. 4611-4621.
Littaua R., Kurane I., and Ennis F.A. 1990. Human IgG receptor II mediates antibody-dependent enhancement of dengue virus infection. The Journal C?! Immunology, 144: p. 3183-3186.
Livingston P.G., Kurane I., Lai C.1., Bray M., and Ennis F.A. 1994. Recognition of envelope protein by dengue virus serotype-specific human CD4+ CD8-cytotoxic T-cell clones. J Vim!., 68 (5): p. 3283-8.
Loke H., Bethell D.B., Phuong e.X.T., Dung M., Schneider 1., White N.1.,et al. 2001. Strong HLA Class I - Restricted T Cell Responses in Dengue Hemorrhagic Fever: A Double-Edged Sword? The Journal C?fb!fectiolls Diseases, 184: p. 1369-1373.
Lopez Antunano F.1. and Mota 1. 2000. Development of immunizing agents against dengue. Rev Panam Salud Publica., 7 (5): p. 285-92.
Lu Y, Raviprakash K., Leao I.e., Chikhlikar P.R., Ewing D., Anwar A., et al. 2003. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine, 21
(17-18): p. 2178-2189.
Mangada M.M, Endy T.P., Nisalak A, Chunsuttiwat S., Vaughn D.W., Libraty
D.H, et al 2002. Dengue spesific E cell responses in pheripheral blood
mononuclear cell obtained prior to secondary dengue virus infections in Thai
school childreen.
The Journal qf Infectious Diseases,
185: p. 1697-1703.
Mangada M.M., Ennis F.A, and Rothman AL. 2003. Quantitation of dengue
virus specific CD4+ T cells by intracellular cytokine staining.
Journal qf
Immunological Methods,
284 (1-2): p. 89-97.
Marianneau P., Cardona A, Edelman L., Deubel V., and Despres P. 1997. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J. Virol., 71 (4): p. 3244-3249.
Markoff L., Pang XW., Houng HS., Falgout B., Olsen R., Jones E., et al. 2002. Derivation and Characterization of a Dengue Type 1 Host Range-Restricted Mutant Virus That Is Attenuated and Highly Immunogenic in Monkeys. Journal of Virology, 76 (7): p. 3318-3328.
Martinez-Barragim J. and del Angel R.M. 2001.
Identification of a Putative
Coreceptor on Vero Cells That Participates in Dengue 4 Virus Infection. Journal of Virology, 75 (17): p. 7818-27.Matusan AE., Pryor M.J., Davidson AD., and Wright PJ. 2001. Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effects on Enzyme Activity and Virus Replication. Journal qf Virology, 75 (20): p. 9633-43.
McBride WJ.H and Bielefeldt-Ohmann H. 2000. Dengue viral infections; pathogenesis and epidemiology. Microbes and Infection, 2: p. 1041-1050. Men R., Bray M., Clark D., Chanock R.M., and Lai c.J. 1996. Dengue type 4
virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol., 70 (6): p. 3930-37. Modis Y, Ogata S., Clements D., and Harrison S.c. 2003. A ligand-binding
pocket in the dengue virus envelope glycoprotein. PNAS, 100 (12): p. 6986-91.
Modis Y, Ogata S., Clements D., and Harrison S.c. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature, 427: p. 313 - 319. Moreno-Altamirano M.M, Sanchez-Garcia FJ., and Munoz M.L. 2002. Non Fc
Muhareva
R.
2004.
Belajar
dari
wabah
virus
dengue.
http://www. k01)lpassonJ/kQmQas.:~1i!.kL0493/l2/om!!j.htn.1,13-03-2004.
Mune M., Rodriguez R., Ramirez R., Soto Y., Sierra B., Rodriguez Roche R.,et al.
2003. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein
expressed in Pichi a pastoris induced neutralizing antibodies and resistance to
Dengue 4 virus challenge in mice.
Arch Virol.,148
(11): p. 2267-73.
PAHO.
Facing
the
dengue
threat:
a
blueprint
for
action.
http://ww\V.paho.orgiEnglish/HCP/HL'TlYB D/nc w-gcneration-bp. pdf
27-03-2004.
Pang X.W., Zhang M.J, and Dayton AI. 2001. Development of dengue virus replicons expressing HIV-l gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV. BMC Microbiol., 1 (1): 28.
Pang X.W., Zhang M.1., and Dayton AI. 2001. Development of Dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol., ] (1): p. 18.
Polo S., Ketner G., Levis R., and Falgout B. ]997. Infectious RNA transcripts ITom full-length Dengue virus type 2 cDNA clones made in yeast. J Viro!., 71 (7): p. 5366-74.
Pugachev KY., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal e., et al. 2004. High Fidelity of Yellow Fever Virus RNA Polymerase. Journal of Virology, 78 (2): p. 1032-1038.
Pugachev KV., Guirakhoo F., Trent D.W., Monath T.P. 2003. Traditional and novel approaches to tlavivirus vaccines. Inl J Parasilol., 33 (5-6): p. 567-82.
Putnak R., Fuller 1., Vanderzanden L., Innis B.L., and Vaughn D.W. 2003.
Vaccination of Rhesus Macaques against Dengue-2 Virus with A Plasmid
DNA Vasccine Encoding The Viral Pre-Membrane and Envelopes Genes.
Am. J Trop. Med Hyg.,
68 (4): p. 469-476.
Rabablert 1., Dharakul 1., Yoksan S., Bhamarapravati N. 2000.
Dengue virus
specific T cell responses to live attenuated monovalent dengue-2 and
tetravalent dengue vaccines.
Asian Pac
J
Allergy Immuno!.,
18 (4): p.
227-35.
increases immunogenicity and protection from VIruS challenge In Aotus monkeys. Virology, 315 (2): p. 345-52.
Rey F.A 2003. Dengue virus envelope glycoprotein structure: New insight into
its interactions during viral entry. PNAS, 100 (12): p. 6899-6901.
Rico-Hesse R 2003. Microevolution and virulence of dengue viruses.
Adv Virus
Res.,
59: p. 315-41.
Roehrig 1.1. 1997. Immunochemistry of dengue viruses. In DJ. Gubler and G.
Kune:
Dengue and Dengue Hemorrhagic Fever.
Cambridge: University
press. p. 199-219.
Rothman AL. 1997. Viral pathogenesis of dengue infection. In DJ. Gubler and
G. Kune:
Dengue and Dengue Hemorrhagic Fever.
Cambridge: University
press. p. 245-271.
Rothman AL. 2004. Dengue: defining protective versus pathologic immunity.
J
Clin Invest.
113 (7): p. 946-951.
Rothman AL., Kanesa-thasan N., West K., Janus 1., Saluzzo 1.F., and Ennis F.A 2001. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine, 19 (32): p. 4694-9. Rothman AL., Kurane I., and Ennis F.A 1996. Multiple specificities in the
murine CD4+ and CD8+ T-cell response to dengue virus. J Viral.,70 (10): p. 6540-6.
Rothman AL., Kurane I., Lai CJ., Bray M., Falgout B., Men R and Ennis F.A 1993. Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes. Journal of virology, 67 (2): p. 801-806
Sabchaeron A, Lang 1., Chathavanich P., Yoksan S., Forrat R, Attanath P., et al.
Safety and Immunogenecity
of Tetravalent
Life
Attenuated
Dengue
Vaccines In Thai Adult Volunteers: Role of Serotype Concetration, Ratio,
and Multiple Doses.
Am. J Trop. Med Hyg.
66 (3): p. 264-272.
Sabchareon A, Lang 1., Chanthavanich P., Yoksan S., Forrat R, Attanath P., et al.
2004. Safety and immunogenicity ofa three dose regimen of two tetravalent
live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Pediatr Infect Dis J,
23 (2): p. 99-109.
Sardelis M.R., Edelman R., Klein T.A., Innis B.L., Putnak 1.R., Jones 1.W., et al. 2000. Limited Potensial For Transmision Of Live Dengue Virus Vaccine Candidates By Aedes Aegypti and Aedes Albopictus. Am. J Trap. Hyg., 62 (6): p 698-704.
Schmaljohn
A.L and McClain
D. 2001. Alphaviruses
(Togaviridae)
and
Flaviviruses (Flaviviridae).
ht!1L2g_sb~Jltl]]h&d:!J/m !~LQ.boQ}:J.'.0JO~4.htn}, 05-05-1004.Shresta S., Kyle 1.L., Snider H.M., Basavapatna M., Beatty P.R., and Harris E.
2004.
Interferon-Dependent Immunity Is Essential for Resistance to
Primary Dengue Virus Infection in Mice, Whereas T
-
and B-Cell-Dependent
Immunity Are Less Critical. Journal qfJ;7rology, 78 (6): p. 2701-2710. Simon S., Saputra E.J., dan Nirmalasari O. 2004. Dengue hemorrhagic fever: anIndonesian perspective. Majalah Kedokleran Alma Jaya, 3 (1): p. 37-49 Soedarmo S.P. 1998. Masalah demam berdarah dengue di Indonesia. In Sri
Rezeki H. Hadinegoro dan Hindra Irawan Satari: Demam berdarah dengue. Jakarta: FKUl p.1-31.
Soegijanto S. 2004. Aspek imunologi penyakit demam berdarah dengue. In Soegeng Soegijanto: Demam berdarah dengue: tinjauan dan temuan barn di era 2003. Surabaya: Airlangga University Press. p. 11-25.
Soegijanto S., Rantam F.A,
Soetjipto, Sudiana K., dan Priyatna Y. 2004.
Mencermati vaksin dengue rekombinan protein E sebagai calom andalan
vaksin di masa depan. In Soegeng Soegijanto:
Demam berdarah dengue:
tinjauan don temuan barn di era 2003.
Surabaya: Airlangga University
Press. p.79-90.
Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak 1.R., King AD., et al. 2003 Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop A1ed Hyg., 69 (6 Suppl): p. 24-31.
Tacio
RD.
2003.
Dengue
vaccine
developed.
http://v..:ww.mani1atimes.!L~i.!Jj1JjQ!1:;ttL~.OQ:i@1.1 Q/Q91Jit~/ lill! in] i [;11tm J 09-08-2004.
Tim Penanggulangan DBD Departemen
Kesehatan RI. 2004. Kasus Demam
Berdarab
Dengue
(DBD)
di
Indonesia.
hUQ :/;~~l.DLd.~.j)1:~s.g.Q.jdL~ioY0.1.lQ.i:Lci<>L1:tuh~!il1°.(':WDlrD()/o2Q[:0k9l>:h'tIrr~'2_2 OQ :L129J,01-10-2004
Trent D.W., Kinney RM., and Huang C.YH. 1997. Recombinant dengue virus vaccine. In D.l Gubler and G. Kune: Dengue and Dengue Hemorrhagic Fever. Cambridge: University press. p. 61-80.
Troyer lM., Hanley KA, Whitehead S.S., Strickman D., Karron RA, Durbin AP., and Murphy B.R 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am J Trop Med Hyg. 65 (5): p. 414-9.
Valdes K, Alvarez M., Pupo M., Vazquez S., Rodriguez R, and Guzman M.G. 2000. Human Dengue Antibodies against Structural and Nonstructural Proteins. Clin Diagn Lab Immunol, 7 (5): p. 856-857
Van der Most RG., Murali-Krishna K, Ahmed R, and Strauss lH. 2000.
Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine:
Quantitation of the Dengue Virus-Specific CD8 T-Cell Response.
Journal qf
Virology,
74 (17): p. 8094-8101.
Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et at. 1997. Dengue in the early febrile phase: viremia and antibody responses. J bifect Dis,176 (2): p. 322-30.
Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S.,et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J b?fect Dis., 181 (1): p. 2-9.
Wang S., He R, and Anderson R 1999. PrM- and Cell-Binding Domains of the
Dengue Virus E Protein.
Journal (if Virology,
73 (3): p. 2547-2551.
Warke RY., Xhaja K, Martin Kl, Fournier M.F., Shaw S.K, Brizuela N., et al. 2003. Dengue Virus Induces Novel Changes in Gene Expression of Human Umbilical Vein Endothelial Cells. Journal of Virology, 77 (21): p.
11822-11832.
Watts D.M., Porter KR., Putvatana P., Vasquez B., Calampa e., Hayes e.G., et al. 1999. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic. Lancet, 354 (9188): p. 1431-4.
Whitehead S.S., Falgout B., Hanley KA., Blaney, If. lE., Markoff L., and Murphy B.R. 2003. A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys. Journal of Virology, 77 (2): p. 1653-1657.
Whitehead S.S., Hanley KA., Blaney lE. Jr, Gilmore L.E., Elkins W.R.,
and
Murphy B.R. 2003. Substitution of the structural genes of dengue virus type
4 with those of type 2 results in chimeric vaccine candidates which are
attenuated for mosquitoes, mice, and rhesus monkeys.
Vaccine. 21(27-30):
p.4307-16.
WHO, Dengue Vaccine Development, Starns, challenges, and WHO priorities,
http://\vww.cidfa2004 .sld.cu/confcrcnci a/vcr .php?id=91, 06-05-2004.
WHO, http://www.wbo.int/csridon/2004 04 OS/cn!, 05-05-2004.
WorId Health Organization,
1997,
Dengue haemorrhagic fever:
diagnosis,
treatment,
prevention
and
control.
2nd
edition.
http://www.\vho.int/cmc/discases/ebola/Den\.!ucpubJicatio11/00 l-ll.pdf
.
27-4-2004.
World Health Organization, 1997,
httP~i/\\:vv\v.\\JlQ.intl.m~dja~,-GJ1tr~it}J.~tsl~.s;l~d~U7/cnL , 27 -4-2004.
